COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
COVID-19SARS-CoV 2
Interventions
DRUG

Povidone-Iodine Nasal Spray and Gargle

Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.

DRUG

Povidone-Iodine Nasal Spray and Gargle

Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.

DRUG

Povidone-Iodine Nasal Spray and Gargle

Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
lead

Nikita Gupta

OTHER

NCT04364802 - COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients | Biotech Hunter | Biotech Hunter